One of the most significant breakthroughs for patients in 2026 is the regulatory use of "Indication Extrapolation," which allows a biosimilar to be approved for all the same uses as the original drug without repeating every single clinical trial. This means that once a bevacizumab biosimilar proves it works for lung cancer, it can immediately be authorized for colorectal, cervical, and brain...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
thai
French
Spanish
Portuguese
Italiano
Romaian
Portuguese (Brazil)
china